Ask the market
before you commit.

No. Gravity runs on the Aterra Intelligence OS — a structured diagnostic system built on real CPG launch frameworks developed across a decade of product development, retail placement, and go-to-market execution in the natural channel. The output is a scored, multi-dimensional brief with a written recommendation — not a generated essay. On the $1,500 path, it is reviewed and signed by Gustavo Nader personally.

Ask Gravity answers one focused market question — free to start, with paid Core and Pro plans for repeated use. A Gravity Scan is a fixed-scope diagnostic that reads eight dimensions of a complete concept together — market, consumer, format, claims, ingredients, positioning, and execution risk — and returns one verdict: build, refine, reposition, validate, or pause. Start with Ask Gravity while you're still shaping the idea. Run a Scan once you have a specific concept to commit capital to.

Yes. Your submission is used solely to generate your brief. It is not shared, stored for model training, or accessible to third parties. If you are working on something sensitive, the Reviewed Gravity Brief includes a confidentiality commitment.

That is the best time to use it. The brief is designed for concepts at any stage: raw idea, formulated product, existing SKU, or repositioning. The earlier you run the diagnostic, the more capital it protects.

Those platforms give you data. Gravity gives you a decision. The brief synthesizes category signals, consumer language, ingredient complexity, competitive positioning, and execution risk into one written recommendation: build, refine, reposition, validate first, or pause. Analyst-grade output at a founder-accessible price.

The system draws from a structured research library built from public market signals, published category reports, Amazon and digital demand data, consumer review mining, competitive benchmarking, industry transcripts, and Aterra's operator frameworks. Gravity does not claim to replace licensed syndicated datasets — it synthesizes available market evidence into a decision. When a client provides proprietary data, it can be incorporated into the analysis.

Where Gravity is strongest is operator-layer intelligence: Aterra actively tracks signals across social listening, brand case studies, conference sessions (Expo West, BevNET Live, Natural Products), podcast commentary from category operators, and field intelligence built from a decade of product development and natural retail placement. This is the layer most research platforms cannot replicate — pattern recognition drawn from operators who have actually built in this space.

AI synthesis is the last step. It connects the signals. It does not generate the intelligence — the intelligence comes first. All analysis is scoped to the U.S. market.

The Intel Feed is a live signal stream built into the Aterra Intelligence OS. It continuously ingests and categorizes CPG market signals — ingredient trends, consumer behavior shifts, category movements, competitive launches, Amazon demand signals, and social listening data — and routes them into a structured research library. When you submit a brief, the system pulls from this library to surface what is actually moving in your category right now, not six months ago when a report was published.

The system has the deepest signal coverage in functional beverages, supplements, gut health, adaptogens, women's wellness, hydration, mood support, functional snacks, clean-label wellness, powder sticks, and regenerative CPG. If your concept falls outside these areas, we will let you know before accepting your brief.

Plain language. Your concept or product, target consumer, format, key ingredients or claims, and your current situation. No deck, no spreadsheet, no formal document. The intake takes about 15 minutes.

You'll get a scored reading across all eight dimensions and one recommended next move. If you want senior interpretation, 100% of your Scan fee credits toward the Reviewed Gravity Brief within 30 days — reviewed and signed personally by Gustavo Nader, with a 1-hour live session.

A diagnostic is a diagnostic. Said honestly: the brief does not replace legal review, regulatory approval, clinical efficacy assessment, final formulation work, a full financial model, or brand identity. It does not guarantee a launch outcome — no serious advisor sells a guarantee. What it gives you is clarity: a hard read on whether the product architecture is sound, before the money is gone.

On the $1,500 path, the brief is reviewed and signed by Gustavo Nader personally — not a generic AI output.